Peptides DB
Research-centric peptide and protocol reference hub
Study 12 of 17HMG (Human Menopausal Gonadotropin) literaturebiorxiv-preprint · Case report2024

A FSH-secreting pituitary adenoma discovered after ovarian hyperstimulation syndrome: a case report, illustrating pitfalls in the interpretation of serum FSH levels

Normal FSH levels in suspected ovarian hyperstimulation syndrome may indicate an FSH-secreting tumor, highlighting the need for careful hormonal assessment.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the hmg (human menopausal gonadotropin) corpus
0
Preclinical
13
Observational · this one
0
Open-label
3
Randomised
1
Reviews

Summary and findings

This case report discusses a 29-year-old woman with irregular menstruation who was found to have bilateral ovarian tumors. Hormonal analysis revealed elevated estradiol at 737 pg/ml and low luteinizing hormone, while both follicle-stimulating hormone and human chorionic gonadotropin were within normal ranges. The findings led to the discovery of an FSH-secreting pituitary adenoma, which altered the planned surgical approach.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Estradiol elevated at 737 pg/ml.2024

Abstract

The authors’ words, as biorxiv-preprint supplied them

<title>Abstract</title> <p><bold>Background</bold>: Most cases of ovarian hyperstimulation syndrome (OHSS) are caused by infertility treatment using human menopausal gonadotropin (HMG) and human chorionic gonadotropin (hCG). OHSS is widely known to have a “spoke-wheel” appearance on imaging, presenting as bilateral symmetric enlargement of ovaries with multiple cysts of varying sizes. When this spoke-wheel appearance is observed in patients not undergoing infertility treatment, tumor-derived hormones such as follicle-stimulating hormone (FSH) and hCG should be measured. However, pitfalls exist in the interpretation of FSH levels. <bold>Case presentation</bold>: A 29-year-old, gravida 0, para 0 woman visited her local doctor for irregular menstruation and to seek fertility treatment. At the first medical examination, bilateral ovarian tumors were found by ultrasonography, and she was referred to our hospital. Magnetic resonance imaging (MRI) findings of the bilateral ovarian tumors suggested typical OHSS, and thus levels of serum hormones including FSH and hCG were measured to determine whether endogenous follicle-stimulating hormones were the cause. Estradiol was elevated at 737 pg/ml (normal: 28.8-196.8 pg/ml in follicular phase) and luteinizing hormone (LH) was low at < 0.3 mIU/ml (normal: 1.4-15 in follicular phase, 2.1-88 mIU/ml in ovulatory phase). Both FSH and hCG were within normal ranges. Therefore, the ovarian masses seemed to be estrogen-producing neoplasms rather than endogenous OHSS, and surgical resection was scheduled. However, computed tomography of the neck to pelvic region was performed to rule out metastatic ovarian tumors, and indicated a coincidental pituitary lesion, which was pathologically characterized as an FSH-secreting pituitary adenoma. Consequently, the scheduled ovarian surgery was avoided. <bold>Conclusions</bold>: Awareness of MRI findings of OHSS is important to avoid unnecessary invasive procedures. When treating patients who have suspected OHSS on imaging but whose serum FSH is in the normal range, it is also important to know that an unsuppressed FSH level despite the negative feedback effect of high estrogen can suggest an FSH-producing tumor.</p>

Elsewhere in the HMG (Human Menopausal Gonadotropin) corpus

BComparison between the efficacy of short and long GnRH-a protocols as a clinical outcome for viable pregnancies in women undergoing IVF/ICSI Cycles.biorxiv-preprint · 2021 · Clinical pregnancy rates: LAP 33.12% vs SAP 28.23%, p=0.001.HumanBRecombinant Follicular Stimulating Hormone Plus Recombinant Luteinizing Hormone Versus Human Menopausal Gonadotropins- Does the Source of LH Bioactivity Affect Ovarian Stimulation Outcome?biorxiv-preprint · 2021 · Mean number of mature oocytes retrieved: 10 ± 5.8 in rFSH+rLH vs 8.3 ± 4.6 in HP-hMG, p=0.01.HumanBUsing Letrozole Cotreatment With Progestin-Primed Ovarian Stimulation In Women With Polycystic Ovary Syndrome Treated For IVFbiorxiv-preprint · 2021 · 42.22% implantation rate in letrozole group vs. 34.69% in control group, p<0.05HumanBEvaluation of assisted reproductive technology treatment outcomes based on stimulation dosages and anti-Mullerian hormone levelsbiorxiv-preprint · 2022 · Not reported in abstract.HumanBHighly purified-hMG versus rFSH in ovarian hyperstimulation in women undergoing elective fertility preservationbiorxiv-preprint · 2023 · Peak estradiol level was significantly lower in the rFSH group (2547.18±1648.21 pg/mL) than in the hp-hMG group (3468.02±2497.69 pg/mL, P<0.001).HumanCErzhi Tiangui formula ameliorates ovarian aging by enhancing antioxidant defense via Nrf2/HO-1 signaling.europepmc · 2026 · Not reported in abstract.Animal